HIGHLIGHTS from SABCS: APHINITY Trial - Clinical Benefit in Operable HER2-positive Early Breast Cancer patients

Regarder maintenant HIGHLIGHTS from SABCS: APHINITY Trial - Clinical Benefit in Operable HER2-positive Early Breast Cancer patients

HIGHLIGHTS from SABCS: KEYNOTE-522 - Neoadjuvant and Adjuvant Treatment with Pembrolizumab Improves PCR for TNBC

Regarder maintenant HIGHLIGHTS from SABCS: KEYNOTE-522 - Neoadjuvant and Adjuvant Treatment with Pembrolizumab Improves PCR for TNBC

HIGHLIGHTS from SABCS: Opposite Effects on Breast Cancer Incidence with Estrogen and Estrogen Plus Progestin

Regarder maintenant HIGHLIGHTS from SABCS: Opposite Effects on Breast Cancer Incidence with Estrogen and Estrogen Plus Progestin

HIGHLIGHTS from SABCS: Combining Atezolizumab with Neoadjuvant Chemotherapy Does Not Improve Pathologic Complete Response Rates for Patients with Triple-Negative Breast Cancer

Regarder maintenant HIGHLIGHTS from SABCS: Combining Atezolizumab with Neoadjuvant Chemotherapy Does Not Improve Pathologic Complete Response Rates for Patients with Triple-Negative Breast Cancer

HIGHLIGHTS from SABCS: Identification of mechanisms driving acquired chemoresistance in preclinical models of taxane resistance.

Regarder maintenant HIGHLIGHTS from SABCS: Identification of mechanisms driving acquired chemoresistance in preclinical models of taxane resistance.